Pushkal Garg, M.D., serves as the Executive Vice President and Chief Medical Officer at Alnylam Pharmaceuticals Inc., a leading biotechnology company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. Dr. Garg joined Alnylam in 2018, bringing with him a wealth of experience in the pharmaceutical industry and a strong background in medical research and clinical development. In his role, he oversees the company's global clinical development, medical affairs, and pharmacovigilance functions, playing a crucial role in advancing Alnylam's mission to transform the lives of people affected by rare and prevalent diseases. Prior to joining Alnylam, Dr. Garg held several leadership positions at major pharmaceutical companies, including Novartis and Pfizer. At Novartis, he served as the Senior Vice President and Global Head of Development for Neuroscience and Ophthalmology, where he led the development of several innovative therapies. Earlier in his career, while at Pfizer, Dr. Garg was instrumental in the development and launch of multiple blockbuster drugs. His extensive experience in clinical development and his strategic vision have been invaluable to Alnylam as the company continues to expand its pipeline and bring new RNAi therapies to market. Dr. Garg's contributions to the field of medicine extend beyond his corporate roles. He is a recognized thought leader and has published numerous articles in peer-reviewed journals, focusing on clinical development strategies and the advancement of novel therapies. His leadership at Alnylam has been pivotal in driving the company's growth and success, particularly in the development of treatments for conditions such as ATTR amyloidosis, hemophilia, and hypercholesterolemia. Under his guidance, Alnylam continues to set new standards in the biopharmaceutical industry, demonstrating the potential of RNAi therapeutics to revolutionize patient care.